INVO Bioscience, Inc. provided revenue guidance for the second quarter 2019. For the quarter, revenue is expected to increase significantly due to initial commercial scale shipments made to Ferring during April of approximately $275,000 with further shipments anticipated. This product order, coupled with the prorated proportion of the licensing agreement should result in second quarter revenues to be more than $450,000.